NEFECON for IgA Nephropathy
University of North Carolina at Chapel Hill
Description
This study is for patients diagnosed with Primary IgA Nephropathy, a kidney disease . it involves research and is conducted to determine the efficacy and safety of a drug called Nefecon (with the active ingredient, budesonide) The purpose of the study is to look at: • How well Nefecon works for the treatment of kidney disease and more specific for patients with the disease "primary immunoglobulin A nephropathy", called IgAN; and • How safe and effective Nefecon is compared to placebo.
Keywords:
Kidneys
Category:
Drug or Biologic
Phase:3
Qualifications
Age
18 - 99 years
Gender
Any
Study Population
adult patients with IgA nephropathy
Investigator
Amy Mottl
Clinical Associate Professor
Medicine-Nephrology
Recruitment Period End
June 30, 2020
Location
Primary Location
Clinical and Translational Research Center
Burnett-Womack Building, 160 Dental Cir, Chapel Hill, NC 27514, USA
Study Qualifications
Age Range 18 - 99 years
Participant qualification(s) -biopsy of the kidney showing IgA nephropathy done in the last 5 years -protein in the urine
Not eligible if: -transplant (or on the transplant list) -dialysis -type 1 diabetes -heart problems -recent cancer -pregnant
Number of Visits
- » 17 In person visit(s)
17 clinic visits
» 17 Remote visit(s)17 phone calls
Participation Period
6 years
